Combined Sample Extraction and Whole Genome Sequencing

A Contract Award Notice
by GENOMICS ENGLAND LIMITED

Source
Find a Tender
Type
Contract (Services)
Duration
not specified
Value
£29M
Sector
INDUSTRIAL
Published
06 Mar 2025
Delivery
not specified
Deadline
n/a

Concepts

Location

United Kingdom:

Geochart for 1 buyers and 1 suppliers
Genomics England
Revvity
Leaflet | Map tiles by Stamen Design, under CC BY 3.0. Data by OpenStreetMap, under ODbL.

1 buyer

1 supplier

Description

Genomics England is contracting for services to deliver accelerated combined extraction and sequencing services in support of the Generation Study programme.

Total Quantity or Scope

This Contract Award Notice confirms the award of the contract to the successful supplier to provide sample extraction and whole genome sequencing (WGS) and storage of 44,500 samples within a 7-working-day turnaround time (TAT) service. The procurement was originally advertised under Contract Notice 2023/S 000-036294 but see below for further information regarding the change to the procedure. The Generation Study is the NHS-embedded research study delivered through the Newborn Genomes Programme and aims to explore the benefits, challenges, and practicalities of offering WGS to newborns, to accelerate diagnosis and access to treatment for rare genetic conditions. The Study is divided into two stages and this contract covers the second stage of the study, relating to a combined accelerated extraction and whole genome sequencing only. The study has a a target of an end to end 14-working-day service to participant(s) with Day 1 being the day the sample arrives at the sequencing provider and Day 14 being the delivery of the clinical results to the participant(s). Accelerated Delivery Stage - The Authority has determined that to achieve the 14-working-day service to participant(s), the combined accelerated sample extraction and sequencing service must be conducted in no more than 7-working-days. The service will be scaled to process and store up to 7,000 samples per quarter from July 2025 to March 2027. There is no minimum committed volume within the contract, but it is anticipated that 44,500 samples will be processed within the 21 months of live service. The initial contract will run from the contract signature date in March 2025 to 31st March 2027, with an option to extend by up to 12 months.

Award Detail

1 Revvity (Llantrisant)
  • Reference: 008121-2025-gel-he-596-23-1
  • Value: £29,200,000

Renewal Options

One optional extension of up to 12 months, to be agreed by the parties.

Award Criteria

price _

CPV Codes

  • 71900000 - Laboratory services
  • 73111000 - Research laboratory services

Indicators

  • Options are available.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Genomics England intends to award the Accelerated Combined Sample Extraction and Whole Genome Sequencing Service for the Newborns Generation Study to Revvity (UK) Limited. Genomics England published a Prior Information Notice (PIN) on 21st July 2023 (2023/S 000-021150) and engaged with the market to better understand the capability to deliver its requirements. Subsequently a Contract Notice (2023/S 000-036294) was published on 8th December 2023. This open procedure procurement process did not deliver a successful outcome therefore Genomics England decided to negotiate with one supplier as the only provider which submitted a compliant response to the initial mandatory selection criteria. As permitted by Regulation 32(2)(a) of the Public Contract Regulations 2015 (PRC15) in these circumstances, Genomics England moved to a negotiated procedure without prior publication and reasonably determined that Revvity (UK) Limited was the only supplier capable of delivering the services. Negotiations have now concluded and Genomics England is satisfied that there has been no substantial alteration to the draft contract which was originally published in the first procurement process. Genomics England intends to award the Accelerated Combined Sample Extraction and Whole Genome Sequencing Service for the Newborns Generation Study to Revvity (UK) Limited following a mandatory 10-day standstill period ending on 16th March 2025 at 23.59. It is the intention to enter into a contract on 17th March 2025.

Reference

Domains